HighVista Strategies’s Cidara Therapeutics CDTX Stock Holding History

HighVista Strategies’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,928	Closed	-$5.06M	–	166
2025 Q4	$5.06M	Sell	22,928 -47,976	-68%	-$7.75M	1.3%	22
2025 Q3	$6.79M	Buy	+70,904	New	+$4.52M	1.66%	13
2021 Q1	–	Sell	-1,060	Closed	-$42K	–	129
2020 Q4	$42K	Hold	1,060	–	–	0.03%	117
2020 Q3	$60K	Buy	+1,060	New	+$74.9K	0.04%	107

HighVista Strategies's CDTX Position: Q1 2026 in Review

HighVista Strategies sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 22,928 shares — an estimated $5.06M sold.

HighVista Strategies first reported a position in CDTX in Q3 2020 and held it in 4 quarters. The position peaked at $6.79M in Q3 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

HighVista Strategies reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
HighVista Strategies sold 22,928 Cidara Therapeutics shares in Q1 2026, an estimated $5.06M.
HighVista Strategies first reported a position in Cidara Therapeutics in Q3 2020 and held it in 4 quarters.
HighVista Strategies's Cidara Therapeutics position peaked at $6.79M in Q3 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.